Fibrocell Science Inc. is a biotechnology company that specializes in developing personalized therapies for rare skin and connective tissue diseases using gene therapy, ex-vivo cell therapy, and tissue engineering. The company's proprietary autologous fibroblast technology is designed to enhance the production of collagen and other connective tissue proteins to repair damaged skin and tissue.
Fibrocell's lead product candidate, FCX-007, is an investigational gene therapy for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic disorder that causes skin blisters and skin erosion. FCX-007 is designed to genetically modify the patient's own skin cells to produce functional collagen VII protein, which is deficient in patients with RDEB.
In addition to FCX-007, Fibrocell is also developing FCX-013, an investigational gene therapy for the treatment of moderate to severe localized scleroderma, a rare autoimmune disease that affects the skin and connective tissue.
Fibrocell's technology has the potential to address a wide range of rare skin and connective tissue diseases for which there are currently no approved therapies. The company is headquartered in Exton, Pennsylvania.
|
